RetinalGeniX Technologies, Inc.

RetinalGenix Technologies is transforming the future of healthcare by providing advanced solutions for the early detection and treatment of both ocular and systemic diseases. We know that the eyes are the gateway to the body, revealing vital early signs of diseases like Alzheimer's, cardiovascular issues, and diabetes—often before they manifest elsewhere. Our groundbreaking high-resolution retinal imaging, combined with our proprietary DNA/RNA GPS™ pharmacogenetic mapping technology, allows us to detect these conditions earlier, providing doctors with real-time data that leads to faster, more accurate diagnosis and more personalized treatments. Imagine a world where sight-threatening conditions and systemic diseases can be identified before symptoms even begin. With RetinalGeniX, that future is now. Our innovative technologies enable 24/7 remote monitoring, giving healthcare providers the tools they need to assess patient health from anywhere, anytime. This means less reliance on costly, invasive procedures like MRIs or PET scans—cutting both patient time and healthcare costs. We don't stop there. Our platform goes beyond detection. We integrate this cutting-edge retinal data with pharmacogenetic testing to validate new therapeutic approaches, guiding the development of novel drugs and treatments. This holistic approach positions RetinalGeniX at the forefront of medical innovation, providing unparalleled value to physicians, payors, and patients alike. Join us on our mission to prevent blindness, treat systemic diseases early, and improve the quality of life for millions.

• Employees 7
• Founded 2002
• Annual Revenue $0
• Total Funding $653089